The Subject Expert Committee (SEC) on Vaccines has asked Zydus Lifesciences Ltd. to revise its Phase III clinical trial protocol for its Measles, Mumps and Rubella (MMR) Vaccine (Live) I.P. (Freeze Dried). The meeting was held on 29 January 2026 in hybrid mode to review biological and PAC proposals and to advise the Drugs Controller General (India).
AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India, to import and market Durvalumab Solution for Infusion 120 mg/2.4 mL and 500 mg/10 mL, sold under the brand name Imfinzi, for an additional indication in India.
Zydus Lifesciences Limited has reported strong financial results for the third quarter and nine months ended December 31, 2025. The company’s revenue for Q3 FY26 stood at Rs. 68,645 million, showing a growth of 30% compared to the same period last year.
REGENXBIO Inc. said the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its biologics license application (BLA) for RGX-121 (clemidsogene lanparvovec), a one-time gene therapy candidate for Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome.
Pharm.D. from recognized University or equivalent institute. Renewed registration with Gujarat Pharmacy Council under the Pharmacy act, 1948 is must at the time of appointment.
Diploma in Ayurvedic Pharmacy from any recognised University / Institution or board or Faculty of Indian System of Medicine established by law in India and recognised by the Government.
M.Pharma-Master of Pharmacy / MSc Nursing Master of Science in Nursing with one year post-qualification experience in the field of research / Clinical Trial. Institute of Liver and Biliary Sciences, ILBS.
M.Sc. in Biotechnology / Life Sciences and must have qualified National Level JRF fellowship such as CSIR / UGC / DBT JRF and must have experience in pancreatic cancer biology. Regional Centre for Biotechnology